



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-von Willebrand factor [82D6A3] Standard Size Ab03983-10.3

This antibody was created using our proprietary Fc Silent™ engineered Fc domain containing key point mutations that abrogate binding to Fc gamma receptors.

This is a reformatted human IgG1 Fc Silent Fc Silent™ antibody, based on the original human IgG1 format, created for improved compatibility with existing reagents, assays and techniques.

**Isotype and Format:** Human IgG1, Fc Silent™, Kappa

**Clone Number:** 82D6A3

**Alternative Name(s) of Target:** human vWF A3 domain; VWF-A3; vWF

**UniProt Accession Number of Target Protein:** P04275

**Published Application(s):** crystallization, in vivo, inhibition

**Published Species Reactivity:** Baboon, Human

**Immunogen:** The original antibody was purified from murine ascites by Protein A chromatography.

**Specificity:** This antibody is specific for human vWF, A3 domain.

**Application Notes:** This antibody was used as an inhibitor to study platelet adhesion to collagen VI and ECM. It was found to inhibit the binding of von Willebrand factor (VWF) to collagen I and III (Hoylaerts et al., 1997; PMID: 9164855). This antibody was found to have a comparable affinity for baboon vWF as for human vWF and inhibited the binding of baboon vWF to collagen with an inhibitory concentration of 50% (IC<sub>50</sub>) of 3.5 µg/ml. Furthermore, it prevented the binding of VWF to collagen and removed bound VWF from a collagen surface, albeit with a lower efficacy. Moreover, the antithrombotic efficacy of the antibody was evaluated in a modified Folts model in baboons; this antibody was used to inhibit the interaction between collagen and vWF to prevent arterial thrombosis in baboons (Wu et al., 2002; PMID: 11986216). The crystal structure of the antibody's Fab fragment, in complex with the vWF A3 domain, was determined (Staelens et al., 2006; PMID: 16314412).

**Antibody First Published in:** Hoylaerts et al. von Willebrand factor binds to native collagen VI primarily via its A1 domain *Biochem J.* 1997 May 15;324 ( Pt 1)(Pt 1):185-91. doi: 10.1042/bj3240185 PMID:9164855

**Note on publication:** The original publication investigates the interaction mechanism between collagen VI and von Willebrand factor (vWF).

## Product Form

**Size:** 100 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.